Besides, a protective effect on clinical outcome of cervical cancer patients of the RAD51 172TT genotype, has been also reported as a possible consequence of a lower cellular capacity for DSB repair and, in turn, a greater sensitivity to chemotherapeutic agents [36]. The gene discussed is RAD51; the disease is cervical carcinoma.